Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...

In a politically charged business climate, the global banking giant joins peers in ending many diversity, equity, and ...

(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

In 2014, Los Angeles-based Ares went public via a listing on the New York Stock Exchange. Along with its direct lending ...

Josh Gilinski wants $63 million for his newly built Bird Streets mansion and $39 million for a vacant lot in Bel-Air.

JPMorgan Chase's (JPM) private bank reportedly reaped $60B from Latin American clients in the past four years as more ...

Private credit’s role continues to evolve, with a focus on specialized and complex transactions, as public market conditions ...

Asset Management One Co. Ltd. raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.4% during ...

New York State Teachers Retirement System lowered its stake in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 0.2% ...

Kenya BioVax Institute, a state agency, is offering lucrative job opportunities, with salaries exceeding KSh 148,000 per ...

The heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public in a challenging market for ...